Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. May 30, 2018. David Kandzari.

Executive Summary

Positive six-month results – the first-ever data from Medtronic's pilot study of its Symplicity Spyral renal denervation (RDN) system – hold the promise of setting the medtech giant back on track and toward a market opportunity worth billions of dollars. See what the study's principal investigator, David Kandzari, said about it here.

"There are a number of reasons to be excited about these particular data. Hypertension is the leading cause of death and disability worldwide, more than any other disease state and the prevalence of hypertension hasn't changed, it's been relatively stagnant. If anything, [prevalence] has increased but the treatment and control of blood pressure has plateaued and declined so there is an urgent need for alternative therapies for more effective of blood pressure control." –David Kandzari, principal investigator, Piedmont Heart Institute

Click here for a free trial of Medtech Insight

Related Content

Topics

UsernamePublicRestriction

Register

MT122738

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel